Rosenblum Silverman Sutton S F Inc. CA Invests $263,000 in Pfizer Inc. (NYSE:PFE)

Rosenblum Silverman Sutton S F Inc. CA purchased a new position in Pfizer Inc. (NYSE:PFE) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 6,070 shares of the biopharmaceutical company’s stock, valued at approximately $263,000.

Several other large investors also recently modified their holdings of the company. Viridian Ria LLC lifted its stake in Pfizer by 0.9% during the fourth quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 280 shares during the last quarter. M Holdings Securities Inc. lifted its stake in Pfizer by 27.9% during the first quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock valued at $1,692,000 after purchasing an additional 8,693 shares during the last quarter. Annex Advisory Services LLC lifted its stake in Pfizer by 0.7% during the second quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock valued at $2,243,000 after purchasing an additional 382 shares during the last quarter. Princeton Global Asset Management LLC lifted its stake in Pfizer by 14.7% during the first quarter. Princeton Global Asset Management LLC now owns 26,736 shares of the biopharmaceutical company’s stock valued at $1,135,000 after purchasing an additional 3,429 shares during the last quarter. Finally, GYL Financial Synergies LLC lifted its stake in Pfizer by 105.3% during the first quarter. GYL Financial Synergies LLC now owns 22,987 shares of the biopharmaceutical company’s stock valued at $976,000 after purchasing an additional 11,788 shares during the last quarter. 71.81% of the stock is owned by institutional investors.

Several equities research analysts recently commented on the stock. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a research report on Monday. JPMorgan Chase & Co. set a $46.00 price target on shares of Pfizer and gave the company a “neutral” rating in a research report on Monday, July 29th. Morgan Stanley downgraded shares of Pfizer from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $48.00 to $40.00 in a research report on Tuesday, July 30th. UBS Group restated a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. Finally, Goldman Sachs Group restated a “buy” rating and issued a $49.00 price target on shares of Pfizer in a research report on Monday, June 17th. Fourteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $46.56.

Shares of NYSE:PFE opened at $34.66 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.47. The company has a market cap of $194.69 billion, a PE ratio of 11.55, a price-to-earnings-growth ratio of 2.81 and a beta of 0.63. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47. The firm has a 50 day simple moving average of $41.01 and a 200 day simple moving average of $41.72.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The company’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.77 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.8 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be paid a $0.36 dividend. The ex-dividend date is Thursday, August 1st. This represents a $1.44 annualized dividend and a yield of 4.16%. Pfizer’s dividend payout ratio is presently 48.00%.

In other Pfizer news, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the transaction, the insider now owns 80,094 shares in the company, valued at approximately $3,524,136. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Frank A. Damelio sold 153,184 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the completion of the transaction, the executive vice president now owns 489,647 shares in the company, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is intrinsic value?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.